Analysis of SL levels in CD34+ cells derived from the bone marrow of patients who have advanced to the aggressive and refractory blast-phase of CML showed that ceramide levels in leukemic CD34+ cells were significantly lower than in normal CD34+ cells. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.